Cytokinetics (CYTK) Competitors $37.01 +0.42 (+1.15%) Closing price 07/11/2025 04:00 PM EasternExtended Trading$35.93 -1.08 (-2.92%) As of 07/11/2025 07:45 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock CYTK vs. ITCI, GMAB, RDY, MRNA, RGC, VTRS, ASND, QGEN, BPMC, and BBIOShould you be buying Cytokinetics stock or one of its competitors? The main competitors of Cytokinetics include Intra-Cellular Therapies (ITCI), Genmab A/S (GMAB), Dr. Reddy's Laboratories (RDY), Moderna (MRNA), Regencell Bioscience (RGC), Viatris (VTRS), Ascendis Pharma A/S (ASND), QIAGEN (QGEN), Blueprint Medicines (BPMC), and BridgeBio Pharma (BBIO). These companies are all part of the "pharmaceutical products" industry. Cytokinetics vs. Its Competitors Intra-Cellular Therapies Genmab A/S Dr. Reddy's Laboratories Moderna Regencell Bioscience Viatris Ascendis Pharma A/S QIAGEN Blueprint Medicines BridgeBio Pharma Cytokinetics (NASDAQ:CYTK) and Intra-Cellular Therapies (NASDAQ:ITCI) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, media sentiment, institutional ownership, profitability, valuation, dividends, earnings and risk. Which has more risk & volatility, CYTK or ITCI? Cytokinetics has a beta of 0.59, suggesting that its share price is 41% less volatile than the S&P 500. Comparatively, Intra-Cellular Therapies has a beta of 0.69, suggesting that its share price is 31% less volatile than the S&P 500. Which has better earnings & valuation, CYTK or ITCI? Intra-Cellular Therapies has higher revenue and earnings than Cytokinetics. Intra-Cellular Therapies is trading at a lower price-to-earnings ratio than Cytokinetics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCytokinetics$19.22M229.99-$589.53M-$5.29-7.00Intra-Cellular Therapies$680.50M20.64-$139.67M-$0.73-180.64 Do institutionals and insiders have more ownership in CYTK or ITCI? 92.3% of Intra-Cellular Therapies shares are owned by institutional investors. 2.7% of Cytokinetics shares are owned by company insiders. Comparatively, 2.6% of Intra-Cellular Therapies shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Does the media refer more to CYTK or ITCI? In the previous week, Cytokinetics had 9 more articles in the media than Intra-Cellular Therapies. MarketBeat recorded 10 mentions for Cytokinetics and 1 mentions for Intra-Cellular Therapies. Cytokinetics' average media sentiment score of 0.94 beat Intra-Cellular Therapies' score of 0.00 indicating that Cytokinetics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cytokinetics 7 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Intra-Cellular Therapies 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do analysts prefer CYTK or ITCI? Cytokinetics presently has a consensus target price of $70.92, suggesting a potential upside of 91.63%. Intra-Cellular Therapies has a consensus target price of $109.70, suggesting a potential downside of 16.81%. Given Cytokinetics' stronger consensus rating and higher probable upside, equities analysts plainly believe Cytokinetics is more favorable than Intra-Cellular Therapies.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cytokinetics 0 Sell rating(s) 3 Hold rating(s) 10 Buy rating(s) 2 Strong Buy rating(s) 2.93Intra-Cellular Therapies 0 Sell rating(s) 10 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.17 Is CYTK or ITCI more profitable? Intra-Cellular Therapies has a net margin of -14.07% compared to Cytokinetics' net margin of -3,201.47%. Cytokinetics' return on equity of 0.00% beat Intra-Cellular Therapies' return on equity.Company Net Margins Return on Equity Return on Assets Cytokinetics-3,201.47% N/A -43.75% Intra-Cellular Therapies -14.07%-9.93%-8.38% SummaryCytokinetics beats Intra-Cellular Therapies on 10 of the 17 factors compared between the two stocks. Get Cytokinetics News Delivered to You Automatically Sign up to receive the latest news and ratings for CYTK and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CYTK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CYTK vs. The Competition Export to ExcelMetricCytokineticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$4.42B$2.93B$5.55B$9.09BDividend YieldN/A2.41%5.25%4.02%P/E Ratio-7.0020.8528.2620.27Price / Sales229.99266.95408.79151.98Price / CashN/A42.1137.1257.67Price / Book-32.187.638.045.49Net Income-$589.53M-$55.05M$3.19B$250.45M7 Day Performance9.17%8.43%3.62%4.79%1 Month Performance7.65%8.14%5.98%9.59%1 Year Performance-33.89%1.62%29.39%16.41% Cytokinetics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CYTKCytokinetics3.9817 of 5 stars$37.01+1.1%$70.92+91.6%-33.9%$4.42B$19.22M-7.00250ITCIIntra-Cellular Therapies0.6604 of 5 stars$131.87flat$109.70-16.8%N/A$14.05B$680.50M-151.57560GMABGenmab A/S4.092 of 5 stars$20.52+1.1%$37.60+83.2%-20.9%$13.16B$3.12B11.662,682Positive NewsAnalyst ForecastRDYDr. Reddy's Laboratories2.76 of 5 stars$15.08flat$16.95+12.4%-8.8%$12.59B$3.81B22.8527,811MRNAModerna4.2999 of 5 stars$29.90-1.9%$46.61+55.9%-72.3%$11.56B$3.24B-3.425,800Trending NewsAnalyst ForecastRGCRegencell Bioscience0.3534 of 5 stars$18.43-19.8%N/AN/A$11.37BN/A0.0010Gap DownVTRSViatris2.8988 of 5 stars$9.20-1.3%$10.40+13.0%-18.9%$10.80B$14.74B-2.9032,000ASNDAscendis Pharma A/S3.5967 of 5 stars$175.98+1.0%$220.67+25.4%+26.7%$10.76B$393.54M-28.021,017News CoverageAnalyst ForecastQGENQIAGEN3.5744 of 5 stars$47.49-1.8%$49.40+4.0%+17.4%$10.56B$1.98B119.075,765BPMCBlueprint Medicines1.2207 of 5 stars$128.40+0.0%$128.06-0.3%+9.8%$8.29B$508.82M-51.98640Positive NewsInsider TradeBBIOBridgeBio Pharma4.663 of 5 stars$43.50-1.1%$58.85+35.3%+71.3%$8.26B$221.90M-12.32400Analyst Upgrade Related Companies and Tools Related Companies Intra-Cellular Therapies Alternatives Genmab A/S Alternatives Dr. Reddy's Laboratories Alternatives Moderna Alternatives Regencell Bioscience Alternatives Viatris Alternatives Ascendis Pharma A/S Alternatives QIAGEN Alternatives Blueprint Medicines Alternatives BridgeBio Pharma Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CYTK) was last updated on 7/13/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredBanks aren’t ready for this altcoin—are you?Our expert analysts have identified a $100 billion gap in the crypto market. Only one project is perfectly ...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cytokinetics, Incorporated Please log in to your account or sign up in order to add this asset to your watchlist. Share Cytokinetics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CYTK Stock Alerts